Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement Meeting Abstract
| Authors: | Javle, M. M.; Roychowdhury, S.; Kelley, R. K.; Sadeghi, S.; Macarulla, T.; Waldschmidt, D. T.; Goyal, L.; Borbath, I.; El-Khoueiry, A. B.; Yong, W. P.; Philip, P. A.; Bitzer, M.; Tanasanvimon, S.; Li, A.; Pande, A.; Shepherd, S. P.; Moran, S.; Abou-Alfa, G. K. |
| Abstract Title: | Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement |
| Meeting Title: | 2021 Gastrointestinal Cancers Symposium (ASCO GI) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 15-17 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-01-20 |
| Language: | English |
| ACCESSION: | WOS:000636712800033 |
| DOI: | 10.1200/JCO.2021.39.3_suppl.265 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 265 -- Source: Wos |
